Undervalued Medical Companies: IPA https://topn
Post# of 49
(Total Views: 291)
Posted On: 04/02/2022 8:39:12 AM
Undervalued Medical Companies: IPA
https://topnewsguide.com/2022/03/31/undervalu...halb-rshn/
Immunoprecise Antibodies Ltd (NASDAQ:IPA) (TSX.V:IPA): Lastly, it is ImmunoPrecise Antibodies Ltd stock that could be on the radars of investors who are currently looking for undervalued medical stocks.
The company announced that it had signed up for a definitive share purchase agreement by way of which it is going to get control over BioStrand BV, BioKey BV, and BioClue BV through its fully owned subsidiary company ImmunoPrecise Netherlands BV. The companies that the company is taking over are a number of biotech companies and pioneers in the branches of biotechnology and bioinformatics. All the entities are based out of Belgium.
Moreover, the company had come on to the radars of investors earlier this month on March 16 when it announced its financial results for the third fiscal quarter that had ended on January 31, 2022.
ImmunoPrecise managed to bring in total revenues of $4.8 million and that reflected a rise of $0.3 million year on year. The net losses however widened to $3.8 million from $1.3 million a year ago.
https://topnewsguide.com/2022/03/31/undervalu...halb-rshn/
Immunoprecise Antibodies Ltd (NASDAQ:IPA) (TSX.V:IPA): Lastly, it is ImmunoPrecise Antibodies Ltd stock that could be on the radars of investors who are currently looking for undervalued medical stocks.
The company announced that it had signed up for a definitive share purchase agreement by way of which it is going to get control over BioStrand BV, BioKey BV, and BioClue BV through its fully owned subsidiary company ImmunoPrecise Netherlands BV. The companies that the company is taking over are a number of biotech companies and pioneers in the branches of biotechnology and bioinformatics. All the entities are based out of Belgium.
Moreover, the company had come on to the radars of investors earlier this month on March 16 when it announced its financial results for the third fiscal quarter that had ended on January 31, 2022.
ImmunoPrecise managed to bring in total revenues of $4.8 million and that reflected a rise of $0.3 million year on year. The net losses however widened to $3.8 million from $1.3 million a year ago.
(0)
(0)Immunoprecise Antibodies Ltd. (IPA) Stock Research Links
Scroll down for more posts ▼